February 22, 2018 Constellation Pharmaceuticals announced a Phase 2 study of CPI-0610 alone or in combination with ruxolitinib in patients with myelofibrosis. This study is for MF patients who are currently taking ruxolitinib but have a sub-optimal response or for patients who are resistant, intolerant or have lost response to a JAK inhibitor. Click here for more… Read More »CONSTELLATION PHARMACEUTICALS ANNOUNCES A PHASE 2 STUDY FOR MF PATIENTS
February 22, 2018 Constellation Pharmaceuticals announced a Phase 2 study of CPI-0610 alone or in combination with ruxolitinib in patients with myelofibrosis. This study is for MF patients who are currently taking ruxolitinib but have a sub-optimal response or for patients who are resistant, intolerant or have lost response to a JAK inhibitor. Click here for more… Read More »CONSTELLATION PHARMACEUTICALS ANNOUNCES A PHASE 2 STUDY FOR MF PATIENTS
Asana BioSciences announces a Phase II study in patients with myelofibrosis is in progress in the US. Study name: ASN002-101 – PHase 1/2, open-label, uncontrolled, multiple-dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of asn002 in relapsed/refractory lymphoma, myelofibrosis, chronic lymphocytic leukemia and advanced solid tumors https://clinicaltrials.gov/ct2/show/NCT02440685?term=Asana&draw=1&rank=5
Robert Baskin Rosen, the founder and Chairman of the MPN Research Foundation, passed away on Thursday, January 4, from complications following a bone marrow transplant to treat Myelofibrosis. He was 74 years old. A longtime real estate executive who lived in Lincoln Park, he attended Highland Park High School, studied at Brown University, and receieved… Read More »Obituary for Robert Rosen, Chairman and Founder of MPN Research Foundation 1943-2018
January 9, 2018 Celgene has purchased Impact Biologics, who was reviving the drug Fedratinib. Fedratinib is a JAK2 inhibitor, and the trial end points include spleen reduction and symptom relief. Click here for more information about the deal. Further context is provided by MPN Forum who wrote about it’s revival in their December issue. It is… Read More »CELGENE PURCHASES IMPACT ON STRENGTH OF FEDRATINIB
December 21, 2017 MPN Research Foundation partnered with Patient Power to produce a video featuring two MPN researchers – John Crispino of Northwestern and Angela Fleischman of University of California, Irvine. They discussed the highlights of ASH related to polycythemia vera, essential thrombocythemia and myelofibrosis. Watch the video here: If you have any ideas for… Read More »TWO MPN EXPERTS DISCUSS ASH 2017
Doctors at MD Anderson have found that Pentraxin 3 (PTX3) is higher in plasma cells of people with Myelofibrosis compared to people without Myelofibrosis, and that there is a positive correlation between the level of mutated genes a person has (known as allele burden) and PTX3. This study helps us better understand the underlying biology of myeloproliferative… Read More »INCREASED PENTRAXIN-3 CORRELATES WITH THE ACTIVITY OF THE NEOPLASTIC CLONE IN PRIMARY MYELOFIBROSIS
Here are a few expert videos on news from the American Society of Hematology meeting in 2017: Dr. Prithviraj Bose talks about the combination of Ruxolitinb and Sotatercept. The goal of this trial is to help with the anemia that can be exacerbated by use of Ruxolitinib by Myelofibrosis. An Interferon update from Dr. Srdan Verstovsek: https://www.patientpower.info/video/ash-coverage-an-interferon-update-from-an-mpn-expert Dr.… Read More »VIDEOS FROM ASH 2017
November 15, 2017 Incyte is testing to see whether Ruxolitinib is beneficial for people with Essential Thrombocythemia, who are resistance or intolerant to Hydroxyurea. The primary endpoint of this study is platelet and White Blood Cell (WBC) control over 1 year of follow-up. Key secondary endpoints include safety and tolerability as well as complete remission… Read More »INCYTE TO TEST RUXOLITINIB VERSUS ANAGRELIDE IN PEOPLE WITH ESSENTIAL THROMBOCYTHEMIA
November 13, 2017: MPNRF is launching a much needed initiative that could unlock answers about the rare blood cancer myeloproliferative neoplasms and identify new therapeutic targets. There are 300,000 people living with an MPN in the United States. Despite that, very little is known about the diseases, including what the genetic markers are for predicting who will progress to the… Read More »MPNRF PURSUES BOLD NEW INITIATIVE: THE PROGRESSION MARKER PROJECT
